ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/breast/metastatic/triple-negative/subsequent
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Breast / Breast - Metastatic / Triple negative / Subsequent
12
trial(s) found.
NCT07545122
Advanced
Phase 1
Not yet recruiting
A Phase 1a/1b, First Time in Human Study of
CT-202
, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring
Triple Negative
Breast, Colorectal, and Urothelial Cancers
anti-NECTIN4 antibody-drug conjugate
Colorectal cancer
Triple-negative breast cancer
Urothelial carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Linear Clinical Research
NCT06926920
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced
Triple-Negative
Breast Cancer (
GS-US-576-7321
)
anti-Trop2 antibody-drug conjugate
Triple-negative breast cancer
NA
2010 - Darlinghurst - St. Vincent's Hospital - Kinghorn Cancer Center
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
NCT06465069
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors (
NEXUS-01
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT06103864
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic
Triple-negative
Breast Cancer (TROPION-Breast05) (
D7630C00001
)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
antimetabolite
platinum-based antineoplastic agent
taxane
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (COMPLETED)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (COMPLETED)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05867251
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (
AVZO-021-1001
)
CDK2 inhibitor
Breast cancer
Epithelial Ovarian Cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT04947189
Advanced
Phase 1 / Phase 2
Recruiting
4CAST
: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer
CYP17A1 inhibitor
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
NOT Breast cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
ACTRN12625000203459
Advanced
Phase 1 / Phase 2
Recruiting
An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (
ENG19
)
EnGeneIC Dream Vector-nanocells-delivered,EGFR-targeting
Colorectal cancer
Kidney cancer
Lung cancer
Mesothelioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT04739670
Advanced
Phase 2
Unknown
A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic
Triple Negative
Breast Cancer (
BELLA
)
anti-PD-L1 monoclonal antibody
anti-VEGF monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Breast cancer
Triple-negative breast cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (10)
Not yet recruiting (1)
Unknown (1)
Recruitment Country and State
NSW (10)
QLD (7)
WA (5)
VIC (5)
SA (2)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (7)
Phase 2 (1)
Phase 3 (1)
Trial Type
Advanced (12)
Cancer Therapy Class
PD-1/PD-L1
50%
PD-1
42%
Trop2
25%
PD-L1
25%
Nectin4
17%
VEGF
17%
FR-alpha
8%
SMO
8%
CDK2
8%
CDK4
8%
CDK6
8%
ER
8%
oestrogen axis
8%
IL-2
8%
CYP17A1
8%
androgen axis
8%
CCR8
8%
VEGFA
8%
TP53
8%
TP53 Y220C
8%
EGFR
8%
Facility
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
6009 - Nedlands - Linear Clinical Research (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (2)
6009 - Nedlands - One Clinical Research (2)
3168 - Clayton - Monash Medical Centre (2)
4215 - Southport - Tasman Oncology (1)
2010 - Darlinghurst - St. Vincent's Hospital - Kinghorn Cancer Center
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
5000 - Adelaide - Cancer Research SA (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2500 - Wollongong - Cancer Care Wollongong (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2170 - Liverpool - Liverpool Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2060 - North Sydney - Mater Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
Breast adenocarcinoma
Triple-negative breast cancer
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Urogenital cancer
Gynaecological cancer
Lung cancer
Non-small cell lung cancer
Ovarian cancer
Respiratory tract cancer
Thoracic cancer
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Cervical cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Viral-related cancer
Bladder cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Oesophageal cancer
Endometrial cancer
Exocrine pancreatic cancer
Kidney cancer
Pancreatic adenocarcinoma
Urothelial carcinoma
Male genital cancers
Prostate cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Peritoneal cancer
Primary peritoneal serous carcinoma
Clear cell renal cell carcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Melanoma
Mesothelioma
Renal pelvis cancer
Primary fallopian tube serous carcinoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial carcinoma
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Pleural mesothelioma
Skin cancer
Squamous non-small-cell lung cancer
dMMR solid cancer
Colorectal adenocarcinoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Carcinoma
HER2-negative breast cancer
HER2-positive breast cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy